(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Alx Oncology Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2026 to be $706,141,315, with the lowest ALXO revenue forecast at $706,141,315, and the highest ALXO revenue forecast at $706,141,315. On average, 3 Wall Street analysts forecast ALXO's revenue for 2027 to be $3,526,995,319, with the lowest ALXO revenue forecast at $752,281,230, and the highest ALXO revenue forecast at $7,028,312,771.
In 2028, ALXO is forecast to generate $8,767,586,975 in revenue, with the lowest revenue forecast at $3,460,493,658 and the highest revenue forecast at $15,741,735,498.